BIOPHTA aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form.

Jean Garrec
Jean Cuiné

Elaia Team

Florian Denis

Related articles

BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development. This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.

2024.06.03 / 3min read.